Diabetes Mellitus Type 2
The authors searched for randomized placebo-controlled trials (December 1, 2008 to November 24, 2017) involving 3 pharmacologic classes of antidiabetic medications to compare the effects of these agents on the risk of hospitalization for HF in T2DM patients.
The infection developed within several months of the patients starting SGLT2 therapy and the drug was discontinued in most cases. All patients required surgery and there was 1 reported death.
PIONEER 5 (N=324) was a randomized, double-blind, placebo-controlled, parallel-group, 26-week trial that evaluated the safety and efficacy of oral semaglutide 14mg vs placebo in patients with type 2 diabetes and moderate renal impairment (eGFR 30 to 59mL/min/1.73m2) inadequately controlled with metformin, sulfonylurea alone or in combination with metformin, or basal insulin alone or in combination with metformin.
The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear.
Results showed the overall safety profile of linagliptin in study patients, including adults with kidney disease, was consistent with previous data.
The Omnipod DASH system consists of a discreet, tubeless, waterproof Pod which is worn on the body, and the Personal Diabetes Manager (PDM), a handheld wireless device used to control the Pod.
Researchers performed a retrospective cohort study by identifying patients from the Optum Clinformatics database who were initiated on canagliflozin 300mg or dapagliflozin 100mg from January 1, 2014 to September 30, 2016.
The renal protective benefit was seen in patients with both reduced (eGFR <60mL/min/1.73m2) and preserved (eGFR ≥60mL/min/1.73m2) renal function.
The DURATION-7 study examined the effect of Bydureon or placebo as add-on therapy to insulin glargine, with or without metformin, in adults with T2D.
Farxiga is a sodium-glucose co-transporter 2 (SGLT2) inhibitor currently indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D mellitus.
Using U.S. Medicaid claims (1999-2010) from 5 states, the researchers sought to examine the association between individual sulfonylureas (glyburide, glimepiride, glipizide) and outpatient-originating SCA/VA; glipizide exposure was considered the reference exposure.
Bydrueon BCise is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
The use of abbreviated pathways can reduce drug development costs so products can be offered at a lower price to patients.
The global Phase 3a clinical trial program for Ozempic comprised 8 clinical trials involving more than 8,000 adults with type 2 diabetes.
In clinical trials, treatment with Bydureon BCise resulted in average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds when used as monotherapy or as an add-on to metormin, a sulfonylurea, a thiazolidinedione, or any combination of two of these agents, at 28 weeks.
The FDA Committee's positive recommendation was based on data from the global development program, SUSTAIN, which evaluated the safety and efficacy of once-weekly semaglutide.
Study authors analyzed the occurrence of amputation in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors vs. non-SGLT2 inhibitors, and specifically, canagliflozin.
The American Diabetes Association (ADA) released its first position statement that includes detailed guidelines for psychosocial assessments and care based on factors including age, type of diabetes, and family support system.